Sign In
Buy CRVS
$11.60
-0.0900 (-0.770%)
At Close: Jun 03, 2026
Corvus Pharmaceuticals, Inc. (CRVS) Q1 2025 Earnings Call Transcript
11:06pm, Thursday, 08'th May 2025
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Zack Kubow - Real Chemistry, Investor Relations Leiv Lea - Chief Financial Offi
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results
04:02pm, Thursday, 08'th May 2025
Soquelitinib data from cohorts 1-3 of atopic dermatitis Phase 1 clinical trial demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts
Data continue to demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2
Data from Cohorts 1-3 of trial to be presented in an oral session and poster at the Society for Investigative Dermatology (SID) 2025 Annual Meeting
Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors
04:01pm, Wednesday, 09'th Apr 2025
SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced today that Richard van den Broek, man
Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials
09:30am, Friday, 28'th Mar 2025
Corvus Pharmaceuticals' leading drug candidate is Soquelitinib, which has broad potential across PTCL, atopic dermatitis, and ALPS. Unfortunately, it seems Corvus' early AD data might have disappointe
Corvus Pharmaceuticals: Now At Cruising Altitude
09:29am, Friday, 28'th Mar 2025
Corvus Pharmaceuticals' stock has experienced volatility due to mixed clinical data, particularly from their lead asset soquelitinib's Phase 1 trial in atopic dermatitis. The company has promising dev
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2024 Earnings Call Transcript
07:58pm, Tuesday, 25'th Mar 2025
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q4 2024 Earnings Conference Call March 25, 2025 4:30 PM ET Company Participants Zack Kubow - Real Chemistry, IR Leiv Lea - CFO Richard Miller - CEO Conferen
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
04:01pm, Tuesday, 25'th Mar 2025
Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Data From Cohorts 1-3 anticipated to be Presented in May Initial Results From First Two Cohorts Supports Safety and Efficacy with Oral Agent and N
Data to be presented in oral session and poster at the 16th Annual T-Cell Lymphoma Forum Data to be presented in oral session and poster at the 16th Annual T-Cell Lymphoma Forum
Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
04:01pm, Wednesday, 19'th Mar 2025
SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
04:01pm, Monday, 17'th Mar 2025
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
Trial for this rare genetic disease to be conducted by NIH/NIAID in partnership with Corvus ITK inhibition intended to address dysregulation of T cells that causes ALPS and has been shown to be effect
Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
08:00am, Tuesday, 04'th Feb 2025
BURLINGAME, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will
Data continue to demonstrate a favorable safety and efficacy profile, including improvements in IGA 0 or 1 and EASI 75 scores compared to placebo Data continue to demonstrate a favorable safety and ef
